Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Tweet this
Print
Marion Anliker-Ort, MSc
PhD Student Clinical Pharmacology
Idorsia Pharmaceuticals Ltd, Switzerland
Poster(s):
029: Multiple-ascending Dose Study With ACT-1014-6470, an Oral Complement Factor 5a Receptor 1 Antagonist, Demonstrated Target Engagement by
Ex Vivo
Matrix Metalloproteinase 9 Stimulation
Monday, September 26, 2022
5:00 PM – 7:00 PM
ET
034: Novel Oral Complement Factor 5a Receptor 1 Antagonist ACT-1014-6470 for the Treatment of Rare Inflammatory Diseases: Single-ascending Dose Study Including Food Effect Assessment
Sunday, September 25, 2022
5:00 PM – 7:00 PM
ET
034: Novel Oral Complement Factor 5a Receptor 1 Antagonist ACT-1014-6470 for the Treatment of Rare Inflammatory Diseases: Single-ascending Dose Study Including Food Effect Assessment
Monday, September 26, 2022
5:00 PM – 7:00 PM
ET
